Jefferies Maintains Buy on Denali Therapeutics, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Michael Yee maintains a Buy rating on Denali Therapeutics and raises the price target from $40 to $45.
November 01, 2024 | 5:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies analyst Michael Yee has reaffirmed a Buy rating for Denali Therapeutics and increased the price target from $40 to $45, indicating confidence in the company's future performance.
The increase in the price target from $40 to $45 by Jefferies suggests a positive outlook on Denali Therapeutics' future performance. The reaffirmation of the Buy rating indicates continued confidence from the analyst, which could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100